Skip to main content
Premium Trial:

Request an Annual Quote

SIRS-Lab Licenses DxS' PCR for Sepsis Test

NEW YORK (GenomeWeb News) – German molecular diagnostics firm SIRS-Lab said today that it will use a PCR technology platform from DxS in a sepsis pathogen-detection test in the European Union under a new licensing agreement.
 
SIRS-Lab will use the DxS Scorpions Technology with its Signature sepsis prediction and monitoring test, which it plans to make widely available in the EU in 2009. The companies also have agreed to include an option in the license that would allow SIRS-Lab to use the DxS PCR technology worldwide.
 
SIRS-Lab plans to start using the test in multi-center clinical trials, company CEO Stefan Russwurm said in a statement, and then the firm expects to make it available as an integrated test that will include pathogen detection and monitoring of host response.
 
SIRS-Lab will use transcriptomics biomarkers it has identified that it said indicate sepsis more reliably than other current measures.
 
DxS CEO Stephen Little said that the Scorpions technology's “high sensitivity, speed and specificity” make it ideal for use in infectious disease applications.
 
Financial terms of the agreement were not released.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.